IQV

IQVIA Q2 2024 Revenue Up 2.3% to $3.8B

IQVIA Holdings Inc. has reported its financial results for the second quarter of 2024, showing a revenue of $3,814 million, which marks a 2.3 percent increase compared to the same period in 2023. The company's GAAP net income for the quarter was $363 million, with adjusted EBITDA reaching $887 million. The GAAP diluted earnings per share stood at $1.97, while the adjusted diluted earnings per share were $2.64.

A breakdown of the revenue shows that Technology & Analytics Solutions (TAS) revenue of $1,495 million increased by 2.7 percent on a reported basis and 3.8 percent at constant currency. Research & Development Solutions (R&DS) revenue of $2,147 million increased by 2.4 percent on a reported basis and 3.3 percent at constant currency. Excluding the impact of pass throughs, R&DS revenue grew by 3.5 percent on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $172 million decreased by 2.3 percent on a reported basis but increased by 2.8 percent at constant currency.

The company's R&DS contracted backlog, including reimbursed expenses, reached $30.6 billion, reflecting a 7.7 percent year-over-year increase and an 8.1 percent increase at constant currency. The second-quarter book-to-bill ratio was 1.27x, and for the twelve months ended June 30, 2024, the book-to-bill ratio was 1.26x.

For the first six months of 2024, IQVIA's revenue was $7,551 million, up 2.3 percent on a reported basis and 3.2 percent at constant currency compared to the same period in 2023. TAS revenue was $2,948 million, representing growth of 1.7 percent on a reported basis and 2.4 percent at constant currency. R&DS revenue was $4,242 million, up 2.9 percent on a reported basis and 3.6 percent at constant currency. CSMS revenue was $361 million, up 0.8 percent on a reported basis and 5.0 percent at constant currency.

As of June 30, 2024, IQVIA's cash and cash equivalents were $1,545 million, and debt amounted to $13,258 million, resulting in net debt of $11,713 million. The company's net leverage ratio was 3.25x trailing twelve-month adjusted EBITDA. The operating cash flow for the second quarter was $588 million, and free cash flow was $445 million.

Looking ahead, IQVIA updated its full-year 2024 guidance, expecting revenue to be between $15,425 million and $15,525 million, with adjusted EBITDA between $3,705 million and $3,765 million, and adjusted diluted earnings per share between $11.10 and $11.30.

Today the company's shares have moved -0.1% to a price of $224.57. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS